News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ChinaBio(R) LLC Week in Review: China's Rx Market to Total $315 Billion in 2020


8/5/2013 8:42:49 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD

August 3, 2013 --China’s prescription drug market will total $315 billion in 2020, expanding at a 26% compound annual growth rate from $48 billion in 2012, according to GlobalData; aTyr Pharma, a San Diego startup with a Hong Kong subsidiary, completed a $49 million round to fund its protein drug program; Daewoong Pharma will pay $16 million to acquire Liaoning Baifeng; Foundation Medicine, a US company backed by WuXi PharmaTech, filed for an $86.3 million IPO on NASDAQ; Shanghai Pharma entered an agreement with Shanghai’s Secondary Military Medical University to promote translational medicine; Takeda Pharma was granted CFDA approval for Nesina, a DPP-4 treatment for type 2 diabetes; InSightec Ltd. of Israel reported its ExAblate System, a uterine fibroid treatment, was approved for China marketing; China's State Intellectual Property Office invalidated the patent for Viread, a treatment for HBV and HIV/AIDS developed by Gilead Sciences; and Johnson & Johnson was ordered to pay a fine for enforcing a minimum price policy on its China medical products distributors. More details….

Stock Symbols: (NYSE: WX) (SHA: 601607; HK: 2607) (TO: 4502) (NSDQ: GILD) (NYSE: JNJ)

Help employers find you! Check out all the jobs and post your resume.

Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES